Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine works by activating the mother’s immune system to produce protective antibodies, which are then transferred to the developing baby through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.

• Nearly 85 per cent coverage when immunised four weeks before birth
• Antibodies from the mother transferred through the placenta protect newborns from birth
• Protection possible with 2-week gap before early delivery
• Vaccination during third trimester still offers significant protection for infants

Compelling evidence from current research

The efficacy of the pregnancy RSV vaccine has been established through a comprehensive study carried out throughout England, examining data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing robust and representative data of the vaccine’s practical effectiveness. The study’s conclusions have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study offers healthcare professionals and parents-to-be with confidence in the vaccine’s proven efficacy across diverse populations and circumstances.

The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This stark contrast underscores the vaccine’s essential role in preventing serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.

Study design and parameters

The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospital admissions. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically significant and representative of the broader population, rather than isolated cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology captured actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine performs when delivered across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.

Learning about RSV and its dangers

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for affected infants to breathe and feed effectively. Parents often witness their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their damaged lungs. Whilst most newborns improve through supportive care, a limited though important proportion perish from RSV complications yearly, making vaccination as prevention a critical public health objective for safeguarding the youngest and most vulnerable people in our communities.

• RSV causes inflammation in lungs, leading to serious respiratory problems in infants
• Half of all newborns contract the virus during their first few months alive
• Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
• Over 20,000 UK infants need serious hospital treatment for RSV each year
• A small number of infants die from RSV related complications annually in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme began in 2024, health officials have highlighted the value of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies through the placenta.

The communication from health authorities stays clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.

Regional differences in vaccine uptake

Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data shows robust and reliable protection irrespective of geographical location.

• NHS trusts deploying multiple messaging strategies to reach women during pregnancy
• Regional disparities in vaccine uptake rates across England necessitate strategic intervention
• Community health services modifying schemes to suit specific population needs

Real-world impact and parent viewpoints

The vaccine’s remarkable effectiveness delivers concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the launch of this preventative solution, the 80% decrease in admissions means thousands of infants spared from severe infection. Parents no more face the distressing scenario of watching their newborns gasping for air or labour to feed, symptoms that define severe RSV infections. The vaccine has fundamentally shifted the landscape of neonatal lung health, offering expectant mothers a active means to protect their most at-risk babies during those crucial first weeks.

For families like that of Malachi, whose serious RSV infection caused profound brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab underscores the life-altering consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to pregnant women in their final trimester, converting what was once an unavoidable seasonal threat into a controllable health concern.